
Our Pipeline
F I B R O S I S
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Idiopathic Pulmonary Fibrosis (IPF)
Radiation Induced Pulmonary Fibrosis (RIPF)
Chronic Kidney Disease (CKD)
Non-alcoholic steatohepatitis (NASH)
Androgenic Alopecia (AGA)
Alzheimer's Disease (AD)
Type 2 Diabetes (T2D)
COVID-19
D E R M A T O L O G Y
C N S
M E T A B O L I C
V I R A L

SAMiRNA™ platform technology
Delivery
Beyond the liver to the inflamed, adipogenic, neoplastic tissues
in organs via various RoA
Partnership
If you are interested in partnering with us for the clinical development and the commercialization of novel RNAi therapeutics using our proprietary SAMiRNA™ technology, please contact us at
collaborations@sirnagen.com or fill out a form below.
